Amyloid beta is a peptide that plays a central role in the neurodegenerative pathology of Alzheimer’s disease by aggregating into plaques in the brain. U.S. Food and Drug Administration (FDA) approved ...

An international team of scientists has developed specialized nanoparticles that can reverse the cognitive symptoms of Alzheimer’s disease in mice. The treatment works by repairing the brain’s natural ...

Clumps or plaques of the protein beta-amyloid in the brain are a hallmark of a type of dementia called Alzheimer’s disease. When beta-amyloid plaques form, they disrupt communication between nerve ...

Multiple studies in humans and mouse models indicate that sleep disruptions raise the risk of Alzheimer’s disease (AD) by increasing the accumulation of disease-relevant proteins such as amyloid-beta ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by clearing amyloid plaques from the brain, the modality has been dogged by a ...

Could amyloid-beta fibrils—which form the hallmark plaques of Alzheimer’s disease (AD)—actually protect the brain? That intriguing possibility caught scientists’ attention last year when Lawrence ...

Scientists have long thought that Alzheimer's disease originates in the brain, but new research suggests that a key protein that triggers the disease could be carried to the brain from elsewhere in ...

While amyloid β plaques are hallmarks of Alzheimer’s disease (AD), recent research suggests that they aren’t the only players in the neurodegenerative disorder. Genome-wide association studies and RNA ...

A team has discovered that, in an animal model of Alzheimer's disease, restoring normal sleep by returning to normal the activity of the thalamic reticular nucleus (TRN), a brain region involved in ...